Rapport Therapeutics (NASDAQ:RAPP) CFO Troy Ignelzi Purchases 5,500 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CFO Troy Ignelzi purchased 5,500 shares of the firm’s stock in a transaction dated Wednesday, October 21st. The stock was acquired at an average cost of $26.10 per share, for a total transaction of $143,550.00. Following the completion of the purchase, the chief financial officer owned 15,500 shares of the company’s stock, valued at approximately $404,550. This represents a 55.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Rapport Therapeutics Stock Performance

RAPP opened at $25.06 on Thursday. Rapport Therapeutics, Inc. has a twelve month low of $23.75 and a twelve month high of $52.93. The firm’s 50-day moving average price is $39.86 and its 200 day moving average price is $39.07.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, sell-side analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The trial showed statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score and CGI-BP Severity of Mania score. Rapport plans to advance the treatment into Phase 3, potentially supporting a major expansion of its pipeline value. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts raised their valuations following the results. BTIG lifted its price target to $89, JonesTrading to $82, Raymond James to $86, and HC Wainwright reaffirmed a $66 target; all maintained bullish ratings. Analysts cited the potential for RAP-219 to address a large bipolar-mania market, with estimated peak sales potentially reaching $1 billion. Inside the $1 Billion Blockbuster Opportunity
• Positive Sentiment: CFO Troy Ignelzi purchased 5,500 shares at an average price of $26.10, increasing his direct ownership by 55%. The insider purchase may signal management confidence in the company’s outlook. SEC insider ownership filing
• Neutral Sentiment: Rapport’s Phase 2 success moves RAP-219 toward Phase 3, but investors still face the usual biotechnology risks, including clinical development, regulatory, commercial, and financing uncertainty.
• Negative Sentiment: The clinical win was viewed as narrower than initially hoped. Reports noted that RAP-219 only narrowly met some expectations, which may have encouraged selling after the stock’s strong reaction to the announcement. The company also recently reported quarterly EPS below consensus, underscoring its ongoing losses and development-stage risk. Rapport bipolar data strikes a chord despite missing target

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RAPP shares. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price target on shares of Rapport Therapeutics in a report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday. Citigroup reissued an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. Finally, William Blair began coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Rapport Therapeutics currently has an average rating of “Buy” and a consensus price target of $68.36.

Institutional Investors Weigh In On Rapport Therapeutics

A number of hedge funds have recently modified their holdings of RAPP. TRV GP V LLC acquired a new stake in Rapport Therapeutics during the second quarter worth about $261,709,477. ARCH Venture Management LLC purchased a new position in Rapport Therapeutics during the second quarter worth about $155,376,512. BlackRock Inc. acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $112,500,000. Johnson & Johnson acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $74,360,823. Finally, TRV GP VI LLC acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $40,387,314.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.